Accessibility Menu
Arrow-Thin-Down
S&P 500
6,875.16
+1.2%
+83.47
Arrow-Thin-Down
DJI
47,544.59
+0.7%
+337.47
Arrow-Thin-Down
NASDAQ
23,637.46
+1.9%
+432.59
Arrow-Thin-Down
Bitcoin
$114,314.00
-0.7%
-$806.98
Arrow-Thin-Down
AAPL
$268.97
+2.3%
+$6.15
Arrow-Thin-Down
AMZN
$226.97
+1.2%
+$2.76
Arrow-Thin-Down
GOOG
$269.93
+3.6%
+$9.42
Arrow-Thin-Down
META
$751.73
+1.8%
+$13.37
Arrow-Thin-Down
MSFT
$531.74
+1.6%
+$8.13
Arrow-Thin-Down
NVDA
$191.46
+2.8%
+$5.20
Arrow-Thin-Down
TSLA
$452.42
+4.3%
+$18.70
Daily Stock GainersDaily Stock LosersMost Active Stocks

Is Zoegenix on the Verge of FDA Approval?

By Dave Williamson – Feb 27, 2013 at 6:10PM

Is FDA approval only weeks away for Zoegenix?

In the following video, Motley Fool health-care analyst David Williamson discusses Zoegenix's (ZGNX +0.00%) 30% leap, as the FDA delays approval for its pain medication Zohydro. A delay would make very little sense if the FDA were planning to reject the drug, and the company has stated that the FDA says this delay will be brief. David tells us why this is surprising, and what is driving the market's reaction.

About the Author

Dave Williamson
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
XMFGreenwave4

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services